Case Information
*1 The summaries of the Colorado Court of Appeals published opinions constitute no part of the opinion of the division but have been prepared by the division for the convenience of the reader. The summaries may not be cited or relied upon as they are not the official language of the division.
Any discrepancy between the language in the summary and in the opinion
should be resolved in favor of the language in the opinion.
SUMMARY
October 15, 2020
No. 19CA0186, Smith v. Surgery Center — Torts — Negligence — Negligence Per Se; Hospitals — Corporate Practice of Medicine Doctrine — Vicarious Liability
This case involves claims of negligence and negligence per se against an ambulatory surgical center (ASC) after the plaintiff was severely injured during a procedure to treat her back pain.
Applying the corporate practice of medicine doctrine, the division holds that the ASC was not liable for failing to protect the plaintiff from the treating physician’s negligence. The division also holds that the state and federal regulations that establish the framework for licensing and Medicare reimbursement were not primarily enacted to protect patient safety, and therefore cannot serve as the basis for a negligence per se claim.
COLORADO COURT OF APPEALS
Douglas County District Court No. 15CV30922
Honorable David J. Stevens, Judge Robbin Smith and Doyle Edward Smith, Jr.,
Plaintiffs-Appellees and Cross-Appellants,
v.
Surgery Center at Lone Tree, LLC,
Defendant-Appellant and Cross-Appellee. JUDGMENT REVERSED AND CASE REMANDED WITH DIRECTIONS
Division I
Opinion by JUDGE GROVE Welling and Vogt*, JJ., concur Announced October 15, 2020 Levanthal Puga Braley, P.C., Bruce L. Braley, Brian N. Aleinikoff, Benjamin I. Sachs, Denver, Colorado; Constitutional Litigation, P.C., Robert Peck, Washington D.C., for Plaintiffs-Appellees and Cross-Appellants Wheeler Trigg O’Donnell LLP , Kevin J. Kuhn, Theresa Wardon Benz, Denver, Colorado, for Defendant-Appellant and Cross-Appellee
Burg Simpson Eldredge Hersh & Jardine, P.C., Nelson Boyle, Jessica L. Derakhshanian, Englewood, Colorado, for Amicus Curiae The Colorado Trial Lawyers Association
Davis Graham & Stubbs LLP, Shannon Wells Stevenson, Gabrielle L. Robbie, Denver, Colorado, for Amicus Curiae Coloradans Protecting Patient Access Greenberg Traurig LLP, Ronald J. Tomassi, Jr., Jennifer M. Little, Denver, Colorado, for Amicus Curiae Colorado Ambulatory Surgery Center Association *3 Greenberg Taurig LLP, Jenifer Little, Denver, Colorado; Leon Cosgrove, LLP, Ronald Tomassi, Jr., Coral Gables, Florida for Amicus Curiae Colorado Ambulatory Surgery Center Association
*Sitting by assignment of the Chief Justice under provisions of Colo. Const. art. VI, § 5(3), and § 24-51-1105, C.R.S. 2019. *4
In this negligence action, defendant, Surgery Center at Lone
Tree, LLC (SCLT), appeals the judgment entered on a jury verdict in favor of plaintiffs, Robbin Smith and Doyle Edward Smith, Jr. The Smiths cross-appeal, contending that the trial court violated their constitutional rights by reducing the amount of the jury award under Colorado’s Health Care Availability Act (HCAA). Applying the corporate practice of medicine doctrine, we conclude that SCLT was entitled to judgment as a matter of law. Accordingly, we reverse the trial court’s judgment and remand for entry of judgment in SCLT’s favor. Because of our disposition, we do not consider the constitutional challenges that the Smiths raise on cross-appeal.
I. Background Ms. Smith visited SpineOne Spine & Sport Medical Clinic
(SpineOne) for an evaluation of her back pain. She scheduled a series of transforaminal epidural steroid injections to treat it. After her treating physician, Hashim Khan, M.D., performed an epidural injection into her spine, Ms. Smith lost all feeling in her lower extremities. She was eventually diagnosed with bilateral lower extremity paraplegia secondary to spinal infarct/ischemia and remains permanently paralyzed below the waist. *5 Dr. Khan performed the first procedure , a “bilateral S1, L1 -L2
¶ 3 transforaminal steroid injection using the particulate corticosteroid, Kenalog, ” at SCLT. He did not note any complications during the procedure, but after a short time in the recovery area, the nurse anesthetist, Stacy Cason, determined that Ms. Smith was unable to move her legs. Dr. Khan examined Ms. Smith and decided to transfer her to another medical center, the first of many transfers that would be required. Ms. Smith never regained feeling in her lower extremities. Ms. Smith and her husband filed suit against three
defendants: Dr. Khan, SpineOne (Dr. Khan’s employer), and SCLT (the ambulatory surgical center (ASC) where Dr. Khan performed the procedure). The Smiths settled their claims against Dr. Khan before trial and the trial court dismissed their claims against SpineOne. Only the claims against SCLT proceeded to trial, and only those are at issue in this appeal. The Smiths’ claims against SCLT asserted “corporate
negligence,” “uninformed consent,” and “negligence per se.” Following an eight- day trial, the jury found in the Smiths’ favor and awarded them $14,905,000.00 in damages. Applying the HCAA, *6 §§ 13-64-101 to -503, C.R.S. 2019, the trial court reduced the amount of the verdict by more than half, to $6,974,692.27. SCLT appeals the judgment entered on the jury verdict. Arguing that the HCAA violates, among other rights, the right to a civil jury trial guaranteed by the Seventh Amendment, the Smiths cross-appeal the trial court’s order reducing the amount of damages awarded by the jury. We conclude that the trial court should have dismissed the
corporate negligence and uninformed consent claims against SCLT as a matter of law because, under the corporate practice of medicine doctrine, SCLT was not vicariously liable for any malpractice by Dr. Khan, nor did it owe a duty to Ms. Smith to assume any medical responsibilities that Dr. Khan failed to fulfill. We likewise conclude that the trial court should have dismissed the Smiths’ claim for negligence per se because the state licensing and federal Medicare regulations that they rely on were not enacted primarily for the public’s safety. Based on our disposition of these issues, we do not reach either the evidentiary issues that SCLT raises or the Smiths’ cros s-appeal challenging the constitutionality of the HCAA.
II. Corporate Practice of Medicine SCLT contends that the Smiths’ negligence claims against it
¶ 7 are barred by the corporate practice of medicine doctrine, and thus should not have been submitted to the jury. We agree.
A. Standard of Review and Governing Law We review de novo a trial court’s denial of a motion for directed
verdict or a motion for judgment notwithstanding the verdict.
Parks
v. Edward Dale Parrish LLC
,
(1) the defendant owed her a legal duty of care; (2) the defendant
breached that duty; (3) the plaintiff suffered injury; and (4) the
cause of that injury was the defendant ’ s conduct.
Laughman v.
Girtakovskis
,
B. Relevant Facts This case revolves around Kenalog, a particulate corticosteroid
that Dr. Khan used in Ms. Smith’s procedure. The Smiths argued that Dr. Khan caused Ms. Smith’s injuries while usi ng Kenalog off-label — i.e., in a way that had not been approved by the Food and Drug Administration (FDA) — and that he failed to obtain Ms. Smith’s informed consent to his off -label use of the drug. As relevant to the issues in this appeal, the Smiths claimed that SCLT had a duty to prevent Dr. Khan’s off -label use of Kenalog, or at least to ensure that Ms. Smith had given her informed consent to its off-label use in the event that Dr. Khan failed to obtain such consent. Kenalog is one of a number of medications that SCLT kept on
hand for use in its facility as part of what the trial court found was
a “formu lary. ”
[1]
SCLT did not tell its physicians how they could use
Kenalog or any other drug that it stocked, but it was undisputed at
trial that Kenalog has a wide variety of uses consistent with its
[1]
A formulary is a list of approved prescription drugs maintained by
a healthcare facility or insurance program.
See J.B.D.L. Corp. v.
Wyeth-Ayerst Labs., Inc.
,
¶ 12 Ms. Smith signed three separate consent forms before her
procedure began. The forms each had different titles and, importantly here, different purposes: Patient Consent and Registration (PCR), Evidence of Informed Consent (EIC), and Consent for Anesthesia Services (CAS). The PCR and CAS forms had the SCLT logo on the front page, but the EIC form did not. Ms. Smith discussed the procedure with Dr. Khan, her pre-operative nurse Rhodalyn Roff, and the nurse anesthetist, Ms. Cason. Ms. Smith and Ms. Roff both signed the PCR form. Ms. Smith, Ms. Roff (as a witness), and Dr. Kahn all signed the EIC form. The CAS form was signed by Ms. Smith, Mr. Smith, and Ms. Cason. It was undisputed at trial that no one explained to Ms. Smith
that Kenalog would be used off-label. Nor did the forms that Ms. Smith signed disclose that information.
C. Plaintiffs’ Claims and Trial Court’s Ruling As the Smiths’ trial brief put it, “[t]his case is about [SLCT’s]
failure to protect its patients by allowing a drug called Kenalog to be used for transforaminal epidural injections in the lumbar spine after the manufacture[r] warned it should not be used for epidural injections.” In essence, the Smiths asserted that SCLT had a duty to Ms. Smith that it breached by failing to prevent Dr. Khan from using Kenalog during the procedure or, in the alternative, by failing to ensure that she was fully informed of — and consented to — its off-label use. Along with several other defenses, SCLT maintained that it
could not be held liable for Ms. Smith’s injuries as a matter of law.
Relying on the corporate practice of medicine doctrine, which
prohibits a corporation that employs a physician from interfering
with the physician’s medical judgment, SCLT argued in its motion
for directed verdict, and again in its motion for judgment
notwithstanding the verdict, that because it had no control over Dr.
Khan’s medical decisions, it was not responsible for negligent acts
that Dr. Khan committed during Ms. Smith’s course of treatment,
and that it did not have — and had not assumed — an independent
*11
duty to ensure that Ms. Smith gave her informed consent.
See Daly
v. Aspen Ctr. f or Women’s Health, Inc.
,
D. Applicable Law “ A hospital has certain inherent responsibilities regarding the
quality of medical care furnished to its patients, and to meet this
standard of responsibility, the hospital has a duty to supervise the
competence of its staff .”
Braden v. Saint Francis Hosp.
, 714 P.2d
505, 507 (Colo. App. 1985);
see also Camacho v. Mennonite Bd. of
Missions
,
negligent credentialing claim: “In extending staff privileges to a
doctor, a hospital does not generally expose itself to liability for the
doctor’s negligence unless it knows o r should know of a propensity
on the doctor’s part to commit negligent acts.”
Settle v. Basinger
,
E. Analysis Having outlined these general rules, we turn next to whether
SCLT could be held liable either for permitting Dr. Khan’s off -label use of Kenalog or for failing to obtain Ms. Smith’s informed consent. As we understand the trial court’s ruling, it concluded that by maintaining a formulary that included Kenalog — thereby approving it for use by physicians in its facility — SCLT took on the responsibility of ensuring that those physicians would not use the *14 drug negligently. SCLT’s policy of “controlling the formulary,” the tri al court found, together with its policy of “providing informed consent to patients,” amounted to the practice of medicine.
1. Formulary The decision to administer a certain medication to a patient in
a certain situation is, without question, a medical decision made by a physician alone. Because SCLT could not dictate to Dr. Khan how he could use Kenalog, SCLT cannot be held vicariously liable for Dr. Khan’s negligent administration of that drug. But that is not what the Smiths argue here. Rather, they
contend that once SCLT placed Kenalog on its formulary, it assumed the responsibility of ensuring that the drug would be used safely. We reject this position because it is flatly inconsistent with the corporate practice of medicine doctrine. SCLT did not, by making certain drugs available for use in its facility, dictate to its credentialed physicians how those drugs could be used. Nor could it, because section 25-3-103.7(3) prohibits health care facilities from “ limit[ing] or otherwise exercis[ing] control over the physician ’ s independent professional judgment concerning the practice of medicine or diagnosis or treatment .” This is not to say that a facility like SCLT lacks any control
over the use of its facilities. As divisions of this court have
repeatedly recognized, “a hospital has certain inherent standards to
maintain regarding the quality of medical care furnished to its
patients. ”
Krane
,
2. Failure to Obtain Informed Consent Next, we consider whether the trial court erroneously ruled
that SCLT had an independent duty to ensure that Ms. Smith was
adequately advised of, and consented to, Dr. Khan’s off -label use of
Kenalog. SCLT contends that imposing such a duty runs afoul of
the corporate practice of medicine doctrine and the holding in
Krane
, which states that a health care facility generally has no
obligation to obtain a patient’s informed consent.
inform the patient of the procedure’s substantial risks and obt ain
the patient’s consent.”
Holley v. Huang
,
a. Physician’s Failure to Obtain Informed Consent
Krane
recognizes a narrow exception to the corporate practice
of medicine doctrine, holding that “unless a hospital knows or
should know of a doctor ’ s propensity to commit negligent acts, such
as failing to obtain a patient ’ s informed consent prior to surgery, a
hospital generally is not liable for the negligent acts of its
physicians.”
Khan’s disclosure was inadequate — and that therefore Ms. Smith’s consent was not informed — because Dr. Khan did not explain to her that his injection of Kenalog would be an off-label use of the *19 drug. And, the Smiths contend, SCLT knew or should have known that Dr. Khan was regularly using Kenalog off-label without disclosing that use to patients, and therefore had a duty to step in and give Ms. Smith the information that Dr. Khan did not. We reject this argument because we do not read Krane , or any
case in the series of decisions that used similar “propensity”
language, as imposing a duty on a health care facility to ensure that
a patient has given informed consent in the event that a physician
has failed to properly advise her. To the contrary, tracing this
language back to its origins clarifies that it does nothing more than
recognize one narrow exception to the corporate practice of
medicine doctrine: a hospital may be liable for a physician’s
negligence if it issues credentials to a physician despite the fact that
it knows or should know that the physician has a tendency to act
negligently. For instance, in
Western Insurance Co. v. Brochner
, the
division held that, “
[i]n extending staff privileges to a doctor
, a
hospital does not generally expose itself to liability for the doctor’s
negligence unless it knows or should know of a propensity on the
doctor’s part to commit negligent acts.”
b. Placing Kenalog on the Formulary For many of the same reasons, we conclude that SCLT did not,
by approving Kenalog for use in its facility and keeping the drug on hand, assume a shared responsibility with Dr. Khan of obtaining Ms. Smith’s informed consent. We recognize that the trial court found that because it “kept the drug available for Dr. Khan to use in an off-label fashion, such off- label use was endorsed by [SCLT].” But even viewing the evidence in the light most favorable to the *22 Smiths, we cannot agree that SCLT’s decision to stock Kenalog is tantamount to an “endorsement” of its off -label use. Nor have the Smiths pointed to any evidence in the record suggesting that SCLT — as an entity — actually knew of or supported Dr. Khan’s off -label use of Kenalog in this or any other case. Even if we were to assume that (1) SCLT, as an entity, knew of
Dr. Khan’s off -label use of Kenalog; (2) the off-label use of Kenalog
(or any other drug) is inherently problematic;
[2]
and (3) Ms. Smith
needed to know about the off-label use in order to give her informed
consent,
[3]
the fact remains that Kenalog has many uses that are
[2]
“ Once FDA-approved, prescription drugs can be prescribed by
doctors for both FDA-approved and -unapproved uses; the FDA
generally does not regulate how physicians use approved drugs. ”
United States v. Caronia
,
maintaining a formulary constitutes the practice of medicine, then
any health care facility that creates an approved list of medications
would, by approving certain medications for use, both violate the
corporate practice of medicine doctrine and expose itself to liability
if a physician were to negligently administer one of those
medications. The result would likely be that health care facilities
drug off-label is material to the question of informed consent.
See,
e.g.
,
Shannon v. Fusco
,
would no longer maintain formularies at all, which would work to the detriment of patient care.
c. SCLT-Specific Form
¶ 35 Because it is directly contrary to Krane , which we find
persuasive, we also disagree with the trial court’s ruling that, by providing its own consent form, SCLT “underto ok a duty to obtain informed consent from the patient in this case.” Ms. Smith signed two informed consent forms authorizing the procedure , one of which was on SCLT’s letterhead, and one of which had no letterhead, but was specific to Dr. Khan. (A third form, for anesthesia services, is not at issue.) Among other things, both forms identified the pending procedure and confirmed that Dr. Khan had advised Ms. Smith of its risks and possible complications. In Krane , the patient signed only one consent form, which
“included the printed name and address of the [h] ospital.” 738 P.2d
at 78. But the
Krane
division foresaw the situation in this case,
noting that “even if a hospital does undertake to obtain a patient’s
informed consent to surgery, that fact does not, itself, create any
liability on its part concerning the surgical procedures and risks
*25
involved.”
Id.
This view, which we follow, is consistent with cases
throughout the country that have rejected the argument that a
health care facility assumes the responsibility of obtaining a
patient’s informed consent by using its own form.
See Mele v.
Sherman Hosp.
,
III. Negligence Per Se
¶ 38 SCLT contends that the Smiths’ claim for negligence per se
should not have been submitted to the jury. We agree.
A. Governing Law and Standard of Review “[N]egligence per se provides that certain legislative
enactments such as statutes and ordinances can prescribe the
standard of conduct of a reasonable person such that a violation of
the legislative enactment constitutes negligence.”
Lombard v. Colo.
Outdoor Educ. Ctr., Inc.
,
regulation) are questions of law that we review de novo.
See
Kaltman v. All Am. Pest Control, Inc.
,
B. Relevant Facts The Smiths assert that “[t]wo sets of regulations supported
Plaintiffs’ negligence per se claims: 6 CCR 1011-1 Chap 20 (Colorado ASC Regulations); and 42 CFR 416.40, 41, 42 (Federal ASC Regulations). ” Portions of thes e regulations appear in the record as exhibits, and were referenced by Instruction 32, which stated in full:
At the time of the occurrence in question in this case, the following Colorado and Federal Regulations were in effect: 1. 6 CCR 1011-1 Chap 20, and 2. 42 CFR 416.40, 41, 42 A violation of these Colorado Regulations or Federal Regulations constitutes negligence. The relevant part of the special verdict form included the
following questions:
4. Was the defendant negligent per se in failing to comply with State and Federal regulations? (Yes or No)
. . .
5. Was the negligence per se , if any, of the defendant a cause of any of the injuries, damages, or losses, claimed by the plaintiffs? (Yes or No)
¶ 43 The jury answered “Yes” to each of these questions.
C. Analysis To determine whether these state and federal regulations
listed in Instruction 32 may form the basis for a claim of negligence
per se, we must consider whether they were (1) “enacted for the
pub lic’s safety,” (2) “intended to protect the class of persons of
which the plaintiff is a member,” and (3) “enacted to prevent the
type of harm suffered by the plaintiff.”
Gerrity Oil & Gas Corp. v.
Magness
,
Department of Public Health and Environment (CDPHE) to “annually license and to est ablish and enforce standards for the operation of,” along with a host of other types of health care facilities, “ambulatory surgical centers.” Complementing this licensing requirement, section 25-3-101(1) provides that it is “unlawful . . . to open, condu ct, or maintain any . . . ambulatory surgical center . . . without having first obtained a license from” CDPHE. CDPHE has adopted the regulations required by these two
statutory provisions, which are codified at Department of Public
Health and Environment Ch. 20, 6 Code Colo. Regs. 1011-1.
[4]
They
comprehensively outline various conditions of ASC licensure,
ranging from, among other things, administration to recordkeeping
to sanitation. Ensuring patient safety is an important benefit of the
rules, but it is not their
raison d’être
.
See Lawson v. Stow
, 2014
COA 26, ¶ 4 4 (holding that Colorado’s false reporting statute could
not form the basis of a negligence per se claim because, while it
“relates to public safety to some extent,” its “
primary purpose
. . . is
to conserve finite law enforceme nt resources”) (emphasis added);
see also Burgess v. Religious Tech. Ctr., Inc.
,
and inspection purposes and not for the creation of a standard of conduct to protect individuals ’”) ( citation omitted). Rather, CDPHE adopted the regulations pursuant to its
authority to “annually license and to e stablish and enforce standards for the operation of . . . ambulatory surgery centers ,” § 25-1.5-103(1)(a)(I)(A) . While the rules state that an ASC’s “governing body shall provide facilities, personnel, and services necessary for the welfare and safety of patients,” Dep’t of Pub. Health & Env’t Ch. 20, Reg. 4.1, 6 Code Colo. Regs. 1011-1, those requirements represent a condition of licensure rather than the agency’s core regulatory focus. The regulations therefore cannot serve as the basis for a negligence per se claim. For many of the same reasons, we reach the same conclusion
with respect to the federal regulations listed in Instruction 32. Title 42, chapter IV, subchapter B of the Code of Federal Regulations is titled “Medicare Programs.” Part 416 of that subchapter sets forth regulations pertaining to Ambulatory Surgical Services and *32 Medicare, and section 416.1 [5] sets the “Basis and Scope” of these regulations:
(b) Scope . This part sets forth — (1) The conditions that an ASC must meet in order to participate in the Medicare program; (2) The scope of covered services; and (3) The conditions for Medicare payment for facility services.
42 C.F.R. § 416.1 (2019). These regulations clearly explain what they are intended to
accomplish — the establishment of requirements for an ASC to receive Medicare reimbursement from the federal government. As is true for the rules promulgated by CDPHE, scattered references to factors that may bear on patient safety — like requiring facilities to maintain a “safe environment,” 42 C.F.R. § 416.41 (2019), and to operate on patients “in a safe manner,” 42 C.F.R. § 416.42 (2019) — do not change the fundamental character and purpose of the regulations as a whole. We therefore conclude that the federal [5] This subsection is likewise not in the record, but we take judicial notice of it, together with the entirety of 42 C.F.R. part 416 (2019). *33 regulations in Instruction 32 could not serve as the basis for a negligence per se claim against SCLT.
IV. Remaining Issues Because we conclude that the trial court should have ruled in
SCLT’s favor as a matter of law, we need not address either the evidentiary issues raised by SCLT or the Smiths’ cross -appeal challenging the constitutionality of the HCAA.
V. Conclusion We reverse the judgment and remand the case for entry of
judgment in favor of SCLT.
JUDGE WELLING and JUDGE VOGT concur.
